NTM-LD Treatment Based on GenSeizer Characteristic Gene Capture Strategy
- Conditions
- Non - Tuberculosis Mycobacteria Lung Disease
- Registration Number
- NCT03224065
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Brief Summary
Treatment of non - tuberculosis mycobacteria lung disease is challenging. The current treatment used is from 2007 American Thoracic Society guidelines recommended antibiotic combination therapy, which is lack of validation of clinical studies. More and more studies have confirmed that NTM antibiotic resistant gene will affect the efficacy, such as erm(41), rrl to clarithromycin, rrs to amikacin and so on. This study aimed to compare the efficacy of guideline recommended therapy and optimized therapy according to antibiotic susceptibility - related genotype.Genetic testing is accomplished through GenSeizer's high-throughput gene capture technique.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 246
- Patients met diagnostic criteria of NTM lung disease by ATS/IDSA on 2007
- non-CF Bronchiectasis
- Already on treatment for NTM lung disease
- Appropriate exclusion of other lung diagnosis
- Patients with severe organ dysfunction
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Culture conversion rate up to 18 months The proportion of final sputum conversion to culture negative
- Secondary Outcome Measures
Name Time Method Initial time of sputum culture conversion up to 18 months The time of first sputum conversion to culture negative
Blood routine test every month, up to 18months liver function test every month, up to 18months kidney function test every month, up to 18months Chest CT up to 18 months Chest imaging changes of CT examination
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Haiqing Chu
🇨🇳Shanghai, China
Haiqing Chu🇨🇳Shanghai, ChinaHaiqing ChuContactchu_haiqing@126.com